AU2001271873A1 - Transforming growth factor beta (TGF-beta) blocking agent-treated stem cell composition and method - Google Patents
Transforming growth factor beta (TGF-beta) blocking agent-treated stem cell composition and methodInfo
- Publication number
- AU2001271873A1 AU2001271873A1 AU2001271873A AU7187301A AU2001271873A1 AU 2001271873 A1 AU2001271873 A1 AU 2001271873A1 AU 2001271873 A AU2001271873 A AU 2001271873A AU 7187301 A AU7187301 A AU 7187301A AU 2001271873 A1 AU2001271873 A1 AU 2001271873A1
- Authority
- AU
- Australia
- Prior art keywords
- cells
- tgf
- stem cells
- antisense
- oligomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3233—Morpholino-type ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Developmental Biology & Embryology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21625600P | 2000-07-06 | 2000-07-06 | |
US60216256 | 2000-07-06 | ||
PCT/US2001/021420 WO2002004479A1 (en) | 2000-07-06 | 2001-07-06 | TRANSFORMING GROWTH FACTOR BETA (TGF-β) BLOCKING AGENT-TREATED STEM CELL COMPOSITION AND METHOD |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001271873A1 true AU2001271873A1 (en) | 2002-01-21 |
Family
ID=22806367
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001271873A Abandoned AU2001271873A1 (en) | 2000-07-06 | 2001-07-06 | Transforming growth factor beta (TGF-beta) blocking agent-treated stem cell composition and method |
Country Status (5)
Country | Link |
---|---|
US (1) | US6841542B2 (de) |
EP (2) | EP1301525B1 (de) |
AU (1) | AU2001271873A1 (de) |
CA (1) | CA2412581C (de) |
WO (1) | WO2002004479A1 (de) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1282699B1 (de) | 2000-05-04 | 2012-11-21 | Sarepta Therapeutics, Inc. | Spleisregion-antisensezusammensetzung und verfahren |
US20050287128A1 (en) * | 2001-05-18 | 2005-12-29 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of TGF-beta and TGF-beta receptor gene expression using short interfering nucleic acid (siNA) |
WO2004087862A2 (en) * | 2003-04-01 | 2004-10-14 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Tak1-mediated inhibition of osteogenesis |
CA2532795A1 (en) * | 2003-08-07 | 2005-02-17 | Avi Biopharma, Inc. | Sense antiviral compound and method for treating ssrna viral infection |
US20050222068A1 (en) * | 2003-10-23 | 2005-10-06 | Mourich Dan V | Method and antisense composition for selective inhibition of HIV infection in hematopoietic cells |
US20050171044A1 (en) * | 2003-12-24 | 2005-08-04 | Stein David A. | Oligonucleotide compound and method for treating nidovirus infections |
US20050234002A1 (en) * | 2004-01-23 | 2005-10-20 | Mourich Dan V | Antisense oligomers and methods for inducing immune tolerance and immunosuppression |
US20090280567A1 (en) * | 2004-02-06 | 2009-11-12 | Dharmacon, Inc. | Stabilized sirnas as transfection controls and silencing reagents |
EP1718747B1 (de) * | 2004-02-06 | 2009-10-28 | Dharmacon, Inc. | Stabilisierte rnas als transfektionskontrollen und silencing-reagentien |
US7402574B2 (en) * | 2004-03-12 | 2008-07-22 | Avi Biopharma, Inc. | Antisense composition and method for treating cancer |
KR101147147B1 (ko) * | 2004-04-01 | 2012-05-25 | 머크 샤프 앤드 돔 코포레이션 | Rna 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드 |
ATE510914T1 (de) | 2004-07-02 | 2011-06-15 | Avi Biopharma Inc | Antisinn antibakterielle verfahren und verbindungen |
JP2008505650A (ja) * | 2004-07-12 | 2008-02-28 | ソリン・グループ・イタリア・ソシエタ・ア・レスポンサビリタ・リミタータ | ヒト細胞を増殖させるための装置及び方法 |
US8129352B2 (en) | 2004-09-16 | 2012-03-06 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating ssRNA viral infection |
US7795389B2 (en) | 2004-09-28 | 2010-09-14 | The Board Of Regents Of The University Of Texas System | Antagonizing TGF-beta activity with various ectodomains TGF-beta receptors used in combination or as fusion proteins |
US8357664B2 (en) * | 2004-10-26 | 2013-01-22 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating influenza viral infection |
US7524829B2 (en) * | 2004-11-01 | 2009-04-28 | Avi Biopharma, Inc. | Antisense antiviral compounds and methods for treating a filovirus infection |
US7935811B2 (en) * | 2004-11-22 | 2011-05-03 | Dharmacon, Inc. | Apparatus and system having dry gene silencing compositions |
US7923207B2 (en) | 2004-11-22 | 2011-04-12 | Dharmacon, Inc. | Apparatus and system having dry gene silencing pools |
US7923206B2 (en) * | 2004-11-22 | 2011-04-12 | Dharmacon, Inc. | Method of determining a cellular response to a biological agent |
EP1855694B1 (de) * | 2005-02-09 | 2020-12-02 | Sarepta Therapeutics, Inc. | Antisense-zusammensetzung zur behandlung von muskelatrophie |
US20060223777A1 (en) * | 2005-03-29 | 2006-10-05 | Dharmacon, Inc. | Highly functional short hairpin RNA |
US20060240032A1 (en) * | 2005-03-31 | 2006-10-26 | Hinrichs David J | Immunomodulating compositions and methods for use in the treatment of human autoimmune diseases |
US20060293268A1 (en) * | 2005-05-05 | 2006-12-28 | Rieder Aida E | Antisense antiviral compounds and methods for treating foot and mouth disease |
US7790694B2 (en) * | 2005-07-13 | 2010-09-07 | Avi Biopharma Inc. | Antisense antibacterial method and compound |
US8067571B2 (en) * | 2005-07-13 | 2011-11-29 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
US8329668B2 (en) * | 2005-09-08 | 2012-12-11 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating picornavirus infection |
US8524676B2 (en) * | 2005-09-08 | 2013-09-03 | Sarepta Therapeutics, Inc. | Method for treating enterovirus or rhinovirus infection using antisense antiviral compounds |
US8501704B2 (en) | 2005-11-08 | 2013-08-06 | Sarepta Therapeutics, Inc. | Immunosuppression compound and treatment method |
AU2007223776B2 (en) * | 2006-03-07 | 2014-05-22 | Sarepta Therapeutics, Inc. | Antisense antiviral compound and method for treating Arenavirus infection |
LT2024499T (lt) | 2006-05-10 | 2018-02-26 | Sarepta Therapeutics, Inc. | Oligonukleotido analogai, turintys katijonines jungtis tarp subvienetų |
US8785407B2 (en) * | 2006-05-10 | 2014-07-22 | Sarepta Therapeutics, Inc. | Antisense antiviral agent and method for treating ssRNA viral infection |
US20070265215A1 (en) * | 2006-05-11 | 2007-11-15 | Iversen Patrick L | Antisense restenosis composition and method |
CA2663601C (en) * | 2006-09-22 | 2014-11-25 | Dharmacon, Inc. | Duplex oligonucleotide complexes and methods for gene silencing by rna interference |
US7845686B2 (en) * | 2007-12-17 | 2010-12-07 | S & B Technical Products, Inc. | Restrained pipe joining system for plastic pipe |
US8188060B2 (en) | 2008-02-11 | 2012-05-29 | Dharmacon, Inc. | Duplex oligonucleotides with enhanced functionality in gene regulation |
EP2271748B1 (de) * | 2008-03-20 | 2018-01-17 | University of Florida Research Foundation, Inc. | Verbessern des gefässläsion-zielsuch- und -reparaturpotentials von stammzellen |
EP2376633A1 (de) * | 2008-12-17 | 2011-10-19 | AVI BioPharma, Inc. | Antisense-zusammensetzungen und verfahren zur modulation von kontaktüberempfindlichkeit oder kontaktdermatitis |
CA2779830C (en) | 2009-11-13 | 2020-07-21 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating influenza viral infection |
KR101981705B1 (ko) | 2010-05-28 | 2019-05-24 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | 변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체 |
US8198429B2 (en) | 2010-08-09 | 2012-06-12 | Avi Biopharma, Inc. | Antisense antiviral compounds and methods for treating a filovirus infection |
WO2012031243A2 (en) | 2010-09-03 | 2012-03-08 | Avi Biopharma, Inc. | dsRNA MOLECULES COMPRISING OLIGONUCLEOTIDE ANALOGS HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS |
US8895291B2 (en) | 2010-10-08 | 2014-11-25 | Terumo Bct, Inc. | Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions |
US20140105867A1 (en) * | 2011-03-23 | 2014-04-17 | University Of Florida Research Foundation. Inc. | Blockage of pai-1 in diabetic cd34+ stem cells corrects cellular dysfunction |
US20130085139A1 (en) | 2011-10-04 | 2013-04-04 | Royal Holloway And Bedford New College | Oligomers |
EA202090338A1 (ru) | 2011-11-18 | 2021-04-30 | Сарепта Терапьютикс, Инк. | Функционально-модифицированные олигонуклеотиды и их субъединицы |
US9617506B2 (en) | 2013-11-16 | 2017-04-11 | Terumo Bct, Inc. | Expanding cells in a bioreactor |
EP3613841B1 (de) | 2014-03-25 | 2022-04-20 | Terumo BCT, Inc. | Passives ersetzen von medien |
CN106715676A (zh) | 2014-09-26 | 2017-05-24 | 泰尔茂比司特公司 | 按计划供养 |
MA41795A (fr) | 2015-03-18 | 2018-01-23 | Sarepta Therapeutics Inc | Exclusion d'un exon induite par des composés antisens dans la myostatine |
EP3302489A4 (de) | 2015-06-04 | 2019-02-06 | Sarepta Therapeutics, Inc. | Verfahren und verbindungen zur behandlung von krankheiten und leiden im zusammenhang mit lymphozyten |
WO2017004592A1 (en) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Cell growth with mechanical stimuli |
US11965175B2 (en) | 2016-05-25 | 2024-04-23 | Terumo Bct, Inc. | Cell expansion |
US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
US11702634B2 (en) | 2017-03-31 | 2023-07-18 | Terumo Bct, Inc. | Expanding cells in a bioreactor |
US11624046B2 (en) | 2017-03-31 | 2023-04-11 | Terumo Bct, Inc. | Cell expansion |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5506337A (en) | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
AU5698186A (en) | 1985-03-15 | 1986-10-13 | Summerton, J. | Polynucleotide assay reagent and method |
US5521063A (en) | 1985-03-15 | 1996-05-28 | Antivirals Inc. | Polynucleotide reagent containing chiral subunits and methods of use |
US5166315A (en) | 1989-12-20 | 1992-11-24 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
US5217866A (en) | 1985-03-15 | 1993-06-08 | Anti-Gene Development Group | Polynucleotide assay reagent and method |
RU2212411C2 (ru) | 1989-10-16 | 2003-09-20 | Эмджен Инк. | Полипептид, обладающий гемопоэтической биологической активностью фактора стволовых клеток (варианты), днк (варианты), экспрессирующий вектор (варианты), фармацевтическая композиция для гемопоэтической терапии, способ получения полипептида и способ его использования (варианты) |
JPH07501204A (ja) | 1991-06-28 | 1995-02-09 | マサチューセッツ インスティテュート オブ テクノロジー | 局所的オリゴヌクレオチド療法 |
US5426098A (en) | 1993-09-02 | 1995-06-20 | Celtrix Pharmaceuticals, Inc. | Increase in hematopoietic progenitor cells in peripheral blood by transforming growth factor beta |
US5801154A (en) | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
FR2728584A1 (fr) | 1994-12-22 | 1996-06-28 | Centre Nat Rech Scient | Procede de transfert de gene dans des cellules activees a partir d'un etat de repos |
WO1997040854A2 (en) | 1996-05-01 | 1997-11-06 | Antivirals Inc. | Polypeptide conjugates for transporting substances across cell membranes |
-
2001
- 2001-07-06 WO PCT/US2001/021420 patent/WO2002004479A1/en active Application Filing
- 2001-07-06 EP EP01950928.0A patent/EP1301525B1/de not_active Expired - Lifetime
- 2001-07-06 US US09/900,115 patent/US6841542B2/en not_active Expired - Lifetime
- 2001-07-06 CA CA2412581A patent/CA2412581C/en not_active Expired - Fee Related
- 2001-07-06 AU AU2001271873A patent/AU2001271873A1/en not_active Abandoned
- 2001-07-06 EP EP15183244.1A patent/EP3020804A1/de not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
EP3020804A1 (de) | 2016-05-18 |
CA2412581C (en) | 2013-09-03 |
US6841542B2 (en) | 2005-01-11 |
US20030109465A1 (en) | 2003-06-12 |
EP1301525B1 (de) | 2015-09-02 |
EP1301525A4 (de) | 2004-04-21 |
EP1301525A1 (de) | 2003-04-16 |
WO2002004479A1 (en) | 2002-01-17 |
CA2412581A1 (en) | 2002-01-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6841542B2 (en) | Transforming growth factor beta (TGF-β) blocking agent-treated stem cell composition and method | |
US6586192B1 (en) | Compositions and methods for use in affecting hematopoietic stem cell populations in mammals | |
AU717783B2 (en) | Methods for use of Mpl ligands with primitive human stem cells | |
US5652222A (en) | Selective inhibition of leukemic cell proliferation by bcr-abl antisense oligonucleotides | |
US6627191B1 (en) | Anti-transforming growth factor Beta (TGF-β) treated stem cell composition and method | |
JP2021505207A (ja) | Nkg2dベースの受容体を発現する免疫細胞のフラトリサイドの減少 | |
JP2002502599A (ja) | 増殖され遺伝子的に修飾されたヒト造血幹細胞集団 | |
JP2013541520A (ja) | 幹細胞および/または前駆細胞を動員するための方法 | |
KR100695677B1 (ko) | 안티센스 조성물 및 암-치료 방법 | |
JPH08506087A (ja) | ガン処置のための抗腫瘍薬とアンチセンスオリゴヌクレオチドの組み合わせ | |
AU2007202366B2 (en) | Transforming growth factor beta (TGF-B) blocking agent-treated stem cell composition and method | |
AU785056B2 (en) | C-myc antisense-treated hematopoietic stem cell composition and method | |
US6869795B1 (en) | Antisense compositions and cancer-treatment methods | |
AU4419396A (en) | System for the maintenance, growth and differentiation of human and non-human primate pluripotent stem, progenitor and mature bone marrow cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |